Venus Remedies secures marketing authorization for key cancer drugs

31 July 2023

Building up on its sizeable global presence in the oncology space, Venus Remedies (BSE: 526953), an India-based provider of affordable cancer drugs worldwide, has extended its reach with marketing approvals for key cancer drugs from Philippines, Paraguay, Georgia and Moldova.

Venus, whose shares edged up 2% to 259.05 rupees on the news, said with this, the company has secured 506 marketing approvals for its oncology products across 76 countries.

While Venus has secured marketing approval for topotecan from Philippines, the second largest market in the ASEAN region, where the company has a sizeable presence, it has also reinforced its position as a leading exporter of oncology drugs with product registration for irinotecan in Paraguay, docetaxel in Georgia and topotecan and irinotecan in Moldova.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK